Literature DB >> 16847189

Technetium Tc 99m sestamibi sensitivity in oxyphil cell-dominant parathyroid adenomas.

Benjamin S Bleier1, Virginia A LiVolsi, Ara A Chalian, Phyllis A Gimotty, Jeffrey D Botbyl, Randal S Weber.   

Abstract

OBJECTIVE: A subset of parathyroid adenomas contains a relative overabundance of oxyphil cells that are capable of greater technetium Tc 99m sestamibi tracer uptake and retention than other cell types. We examined whether the presence of oxyphil cells augments the sensitivity of technetium Tc 99m sestamibi preoperative localization and whether the histologic findings of a lesion could be predicted based on the adenoma mass and serum calcium and parathyroid hormone levels.
DESIGN: Retrospective, single-blinded comparison of technetium Tc 99m sensitivity rates, lesion mass, and preoperative serum calcium and parathyroid hormone values of patients with chief and mixed cell-dominant adenomas and those with oxyphil-dominant parathyroid adenomas.
SETTING: Tertiary care university hospital. PATIENTS: Sixty-three patients diagnosed as having a parathyroid adenoma. INTERVENTION: All patients underwent resection of a parathyroid adenoma following a preoperative technetium Tc 99m sestamibi localization study and serum calcium and parathyroid hormone level analysis. MAIN OUTCOME MEASURE: Technetium Tc 99m sensitivity rate.
RESULTS: The overall technetium Tc 99m sestamibi sensitivity rate was 76.2%. The sensitivity within the chief and mixed cell-dominant (n = 52) and oxyphil cell-dominant groups (n = 11) were 71.2% and 100%, respectively (P = .04). There was no correlation between histologic findings of the lesion and its size or serum calcium and parathyroid hormone levels.
CONCLUSIONS: Oxyphil cell predominance within an adenoma augments technetium Tc 99m sestamibi scan sensitivity in a statistically significant manner. The use of technetium Tc 99m sestamibi preoperative localization may therefore be differentially greater in patients with these types of lesions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16847189     DOI: 10.1001/archotol.132.7.779

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  7 in total

1.  Functioning oxyphil parathyroid adenoma: a case report.

Authors:  Rajendra B Metgudmath; Vinita V Metgudmath; Prakash R Malur; Amal T Das; Anjali R Metgudmath
Journal:  J Clin Diagn Res       Date:  2014-04-15

2.  Oxyphil Cell Parathyroid Adenomas Causing Primary Hyperparathyroidism: a Clinico-Pathological Correlation.

Authors:  Pamela Howson; Schelto Kruijff; Ahmad Aniss; Thomas Pennington; Anthony J Gill; Tristan Dodds; Leigh W Delbridge; Stan B Sidhu; Mark S Sywak
Journal:  Endocr Pathol       Date:  2015-09       Impact factor: 3.943

Review 3.  Oncocytic mania: a review of oncocytic lesions throughout the body.

Authors:  F Guaraldi; G Zang; A P Dackiw; P Caturegli
Journal:  J Endocrinol Invest       Date:  2011-02-07       Impact factor: 4.256

4.  Primary hyperparathyroidism due to atypical vertically long cystic adenoma.

Authors:  Sachiko-Tsukamoto Kawashima; Takeshi Usui; Yohei Ueda; Maiko-Kakita Kobayashi; Mika Tsuiki; Kanako Tanase-Nakao; Kazutaka Nanba; Tetsuya Tagami; Mitsuhide Naruse; Yoshiki Watanabe; Ryo Asato; Sumiko Kato; Akira Shimatsu
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2014-10-01

5.  Ultrastructure of Hyperfunctioning Parathyroid Glands: Does it Explain Various Patterns of 99mTc-sestamibi Uptake.

Authors:  Abdelhamid H Elgazzar; Jehoran T Anim; Shorouk F Dannoon; Medhat M Farghaly
Journal:  World J Nucl Med       Date:  2017 Apr-Jun

6.  Substernal oxyphil parathyroid adenoma producing PTHrP with hypercalcemia and normal PTH level.

Authors:  Angela Gurrado; Andrea Marzullo; Germana Lissidini; Agostino Lippolis; Domenico Rubini; Gaetano Lastilla; Mario Testini
Journal:  World J Surg Oncol       Date:  2008-02-21       Impact factor: 2.754

7.  Case report: incidental parathyroid adenoma in a Chinese diabetic patient with hypercalcemia and normal parathyroid hormone levels.

Authors:  Can Pang; Youben Fan; Huizheng Zhang; Haoyong Yu; Bomin Guo; Jie Kang; Xianzhao Deng; Yuqian Bao
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.